A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation
about
Imiglucerase in the treatment of Gaucher disease: a history and perspectiveBiomanufacturing of protective antibodies and other therapeutics in edible plant tissues for oral applicationsPlant-based solutions for veterinary immunotherapeutics and prophylacticsCharacterization of gene-activated human acid- -glucosidase: Crystal structure, glycan composition, and internalization into macrophagesCyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analoguesMolecular pharming's foot in the FDA's door: Protalix's trailblazing storyCharacteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.Hemorrhagic aspects of Gaucher disease.Gaucher disease and its treatment options.Gaucher disease: clinical profile and therapeutic developments.Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds.Oligomerization status influences subcellular deposition and glycosylation of recombinant butyrylcholinesterase in Nicotiana benthamiana.Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher DiseaseRecent advances towards development and commercialization of plant cell culture processes for the synthesis of biomoleculesTransgenic Production of an Anti HIV Antibody in the Barley EndospermAn evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher diseaseInvestigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes.Application of a Scalable Plant Transient Gene Expression Platform for Malaria Vaccine Development.Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.Plant-made vaccine antigens and biopharmaceuticals.Emerging drugs for lysosomal storage diseases.Transient expression systems for plant-derived biopharmaceuticals.Plant-derived vaccines and other therapeutics produced in contained systems.Plant-made pharmaceuticals: leading products and production platforms.Evolution of plant-made pharmaceuticals.Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.Recombinant plant-derived pharmaceutical proteins: current technical and economic bottlenecks.Management of bone disease in Gaucher disease type 1: clinical practice.Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.New Directions in Gaucher Disease.Inhibition of protease activity by antisense RNA improves recombinant protein production in Nicotiana tabacum cv. Bright Yellow 2 (BY-2) suspension cells.Human α-mannosidase produced in transgenic tobacco plants is processed in human α-mannosidosis cell lines.Cell cycle distribution, cellular viability and mRNA expression of hGCase-gene-transfected cells in dairy goat.Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.From gene to harvest: insights into upstream process development for the GMP production of a monoclonal antibody in transgenic tobacco plants.Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease.RTB Lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapiesProduction of active human glucocerebrosidase in seeds of Arabidopsis thaliana complex-glycan-deficient (cgl) plants.Expression of Multiple Taenia Solium Immunogens in Plant Cells Through a Ribosomal Skip Mechanism.
P2860
Q24631426-2216A201-9674-460B-9C85-1DB899AD0966Q26766215-1523B8AD-C1A5-4EF8-9FB9-B60E09073FBFQ27000876-F48911E5-33D5-4AA9-A416-1678C57738F1Q27657379-E6866DFF-B77D-481E-B582-4AA7FD12D255Q27667205-47F49F7E-21BB-4421-B6CB-615DE550C1DAQ28086959-80CD42F5-F405-4CCF-B19C-3F2E77367A79Q33401459-340457BB-1EAC-44E7-A0CB-E152B9B58F5DQ33418647-B0F1A73F-C8BD-433A-872A-5C87F1A6FAF7Q34386658-DF82B58C-9255-4A69-B206-82ED1CB820A9Q34443517-B9D64C28-18F8-4FC2-ACBB-039F36B3DC8BQ34464236-291198C6-8FE8-4AB8-BC8C-76690A4401B5Q34693466-F9CCA6BB-EC50-4E48-BF70-26BDB2754125Q35028532-EEFD4FE3-4F7B-4358-BC8E-4C8FCE26ABF6Q35656456-81226553-60AE-44ED-960D-3C61B8D86D0BQ35784729-89C1FA66-BC1A-4E97-BD58-453D04B811BDQ35804905-539CD729-85BF-49E4-A409-779087AECC74Q35997277-3F534F90-8975-4582-8CDA-690DC5A75BB0Q36282478-4DE0F984-8ABB-4A59-BA63-EA28D017BCFBQ36396520-C385365C-2035-40FA-A58E-584B014DE90DQ37354438-5FF53F16-4341-4108-A18A-D5F75DF7DB9EQ37616370-207C22B3-EAD8-496F-8394-8E77A2341DC2Q37765901-4173C72E-87DB-4F2D-93C0-E0AAF560BF62Q37776717-A541EC13-05CE-41A7-BB58-56B9D03BDE99Q37776718-98F3C0A6-B9C5-4773-9FA3-E5FD7014CEE1Q37859060-A944980D-E6CF-4D4D-8784-E8FA297B55DEQ37891688-B83D003D-AA9F-43D9-BA0F-B223FD1541DCQ38048706-D82F4998-1FF9-4192-BE67-DD9AB8FE237AQ38232409-7CBD6E47-6BB4-4816-B155-C468B850FFBDQ38290826-5A2295ED-EA6B-4577-BD4A-4054F9F37AF3Q38684097-E7FAC149-1A4C-4484-B90E-77DF0442F8F7Q38905996-7A670B35-1CEE-4B0F-AE39-A81372D9A6BFQ38995002-0E04295C-6AD3-4DB8-B25E-75FCD1525928Q39529964-A8669905-2FD6-4D85-9E5E-8C27AB3E678EQ39733816-259AF8C9-890F-437A-9190-98082B12252BQ40108800-60A04034-68B9-494A-BEE7-23606C1B971AQ40692385-D279EF81-0D59-44B1-8A2C-DE43A75601F4Q41365905-ADD89F88-E988-4B43-B5A2-617E564F8C0BQ41977743-7DCD360C-D96E-4A4F-8244-37E1512E7588Q42077651-E4374336-BD27-4D9B-8BEC-DED267884CF8Q42155657-6F496174-6D19-4028-A4C1-FF36E61BAB9E
P2860
A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A plant-derived recombinant hu ...... ical and phase I investigation
@ast
A plant-derived recombinant hu ...... ical and phase I investigation
@en
A plant-derived recombinant hu ...... ical and phase I investigation
@en-gb
A plant-derived recombinant hu ...... ical and phase I investigation
@nl
type
label
A plant-derived recombinant hu ...... ical and phase I investigation
@ast
A plant-derived recombinant hu ...... ical and phase I investigation
@en
A plant-derived recombinant hu ...... ical and phase I investigation
@en-gb
A plant-derived recombinant hu ...... ical and phase I investigation
@nl
altLabel
A Plant-Derived Recombinant Hu ...... ical and Phase I Investigation
@en
prefLabel
A plant-derived recombinant hu ...... ical and phase I investigation
@ast
A plant-derived recombinant hu ...... ical and phase I investigation
@en
A plant-derived recombinant hu ...... ical and phase I investigation
@en-gb
A plant-derived recombinant hu ...... ical and phase I investigation
@nl
P2093
P2860
P1433
P1476
A plant-derived recombinant hu ...... ical and phase I investigation
@en
P2093
Ari Zimran
Arnold Freeman
Daniel Bartfeld
David Aviezer
Einat Brill-Almon
Sarah Mizrachi
Sharon Hashmueli
Yael Liberman
Yoseph Shaaltiel
P2860
P356
10.1371/JOURNAL.PONE.0004792
P407
P50
P577
2009-01-01T00:00:00Z